DMC demonstrates full commercial scale at record speed
Boulder, CO, USA: 15 March 2021 – DMC Biotechnologies has successfully demonstrated full commercial scale (85m3 fermentation at EW Biotech, Germany) for its first product, the amino acid L-alanine.
The scale-up results identically tracked the performance at bench and pilot scales, further validating the predictability and scalability of DMC’s Dynamic Metabolic Control technology. Importantly, commercial performance metrics were demonstrated, meaning that no further strain improvements are required to achieve the target selling price.
This demonstration of process robustness and predictability across scale of production – from high-throughput screening to full commercial scale has never been demonstrated in the field and represents a major advancement for DMC. This core technology enablement will also be beneficial for DMC’s pipeline of products that will be scaled and commercialized next.
More information on DMC’s website.